within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB05_InterferonAlfa2b;

model InterferonAlfa2b
  extends Pharmacolibrary.Drugs.ATC.L.L03AB05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>InterferonAlfa2b</td></tr><tr><td>ATC code:</td><td>L03AB05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Interferon alfa-2b is a recombinant cytokine with antiviral, antiproliferative, and immunomodulatory activities. It is historically used for treatment of chronic hepatitis B and C, malignant melanoma, hairy cell leukemia, and several other viral infections and cancers. It is approved in several countries but its use has declined with the advent of more modern agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers after single subcutaneous dose.</p><h4>References</h4><ol><li><p>Miyachi, N, et al., &amp; Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. <i>Clinical drug investigation</i> 41(4) 391â€“404. DOI:<a href=\"https://doi.org/10.1007/s40261-021-01026-5\">10.1007/s40261-021-01026-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33725322/\">https://pubmed.ncbi.nlm.nih.gov/33725322</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end InterferonAlfa2b;
